1 / 30

Drs. Yi Tsong 1 , Xiaoyu (Cassie) Dong* 1 , Meiyu Shen 1 & Richard T. Lostritto 2

Quality Assurance Test of Delivered Dose Uniformity of Multi-dose Spray and Inhalation Drug Products. Drs. Yi Tsong 1 , Xiaoyu (Cassie) Dong* 1 , Meiyu Shen 1 & Richard T. Lostritto 2 1: Office of Biostatistics/Office of Translational Sciences, CDER, FDA

eurich
Download Presentation

Drs. Yi Tsong 1 , Xiaoyu (Cassie) Dong* 1 , Meiyu Shen 1 & Richard T. Lostritto 2

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Quality Assurance Test of Delivered Dose Uniformity of Multi-dose Spray and Inhalation Drug Products Drs. Yi Tsong1, Xiaoyu (Cassie) Dong*1, Meiyu Shen1& Richard T. Lostritto 2 1: Office of Biostatistics/Office of Translational Sciences, CDER, FDA 2: Office of Pharmaceutical Quality, CDER, FDA 2015 MBSW

  2. Disclaimer • This article reflects the views of the authors and should not be construed to represent FDA’s views or policies. 2015 MBSW

  3. Outline • Introduction • USP<601> DDU Test • Two One-Sided Tolerance Intervals (TOSTI) DDU Test • FDA Large Sample DDU Proposal • Summary • Main References 2015 MBSW

  4. I. Introduction 2015 MBSW

  5. Multi-dose Inhaler/Spray • A multi-dose inhaler/spray (MDI) delivers a specific amount of drug in aerosol or solution form. • Multi-dose nasal sprays are commonly used to treat allergy related symptoms. Multi-dose nasal spray http://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a6eaedb3-5c96-4859-be43-a48c9c818bc7&type=display 2015 MBSW

  6. Delivered Dose Uniformity (DDU) • The delivered dose measures the amount of medication delivered to the patients and should be close to the target dose as label claimed. • Uniformity of the delivered dose is a critical quality attribute (in-vitro performance) to ensure the quality, efficacy and safety for of MDI products. • DDU is an important requirement for batch release and quality assurance. 2015 MBSW

  7. II. <USP> 601 DDU Test 2015 MBSW

  8. Tier 1, 10 containers (10 beginning, 10 end) If 3~6 out of 20  (80,120) At most 2 of 20 (80%, 120%) None is outside (75%, 125%) Average of each 10 (85%,115%) Tier 2, additional 20 containers (20/20) Yes At most 6 of 60  (80%,120%) None is outside (75%, 125%) Average of each 30 (85%,115%) No Complies Yes Not complies Complies USP<601> DDU Test • The test for DDU in the FDA 1999 Draft Guidance was adopted into the 2011 in-process revision of USP <601>. 2015 MBSW

  9. USP<601> DDU Test • A counting method: converts a continues variable (DD) into a binary variable (outside/inside): Sampling by Variable vs. Sampling by Attribute • Only applicable to the samples, not for inference on the entire batch. • No clear definition of the product quality; • Not a statistically based sampling plan. • The sample is OK ≠ The batch is OK. • Zero Tolerance Outside (75%, 125%): • To detect extreme data. • It is no effect for small sample; • Not reward large samples; 2015 MBSW

  10. USP<601> DDU Test Is the USP DDU test a batch release test? Is the USP test a stringent test for batch release? No. Whenever tested, the product needs to meet the USP acceptance criteria. Thus, a batch release test is usually more stringent than the USP test. Can the USP test make inference on the entire batch? No. Only applicable to the samples, not for inference on the entire batch. • Needs a statistically sound approach for batch release: the tolerance interval approach controls the coverage within a specific interval (say 80 – 120%LC). 2015 MBSW

  11. III. Two One-sided Tolerance Intervals DDU Test 2015 MBSW

  12. Two One-sided Tolerance Intervals Procedure (TOSTI) • In 2003, IPAC-RS (International Pharmaceutical Aerosol Consortium on Regulation and Science) proposed a two-sidedtolerance interval approach as an improvement for the control of DDU of orally inhaled and nasal drug products. • Coverage as the quality requirement; • In 2005, FDA proposed a two one-sided tolerance intervals (TOSTI) procedure to test if the batch complies and presented this procedure to the Advisory Committee of Pharmaceutical Science, in October 2005. • Coverage as the quality requirement; 2015 MBSW

  13. p2 p1 safety efficacy TOSTI - Product Quality Definition • Two-sided TI: Most lot (>P%) within (80%, 120%) • Two one-sided TIs: Not much outside each end of (80%, 120%) • WITH 95% CONFIDENCE 2015 MBSW 13

  14. TOSTI - Statistical Hypotheses • Small sample n1=10/10/20/20, P = 87.5%, L=80, U=120: • Reject H0 if • With L= 80% LC, U = 120% LC, PU = PL = 6.25% and Pocock alpha spending function, K1 = 2.45 at the 1st tier and K2 = 1.94 at the 2nd tier. Efficacy Safety Safety 2015 MBSW 14

  15. TOSTI – Test Flow Chart Tier 1, 10 containers (10 beginning, 10 end) Tier 2, additional 20 containers (20 beginning, 20 end) Average of each 10 (85%,115%) Yes Average of each 30 (85%,115%) Complies No Not complies Yes 2015 MBSW Complies

  16. TOSTI vs. USP<601> Reference: Parametric Tolerance Interval Test for Delivered Dose Uniformity (DDU) Working Group Update, Moheb M. Nasr, Ph.D., Advisory Committee of Pharmaceutical Science October 25, 2005 2015 MBSW

  17. TOSTI vs. USP <601> Acceptance probability of two one-sided tests and USP <601> DDU method for two-tier multiple-dose (10/10/20/20) with batch of on-target and off-target means. 2015 MBSW 17

  18. The requirement of the sample means between 85% and 115% almost has no impact on the acceptance probabilities for TOSTI. Acceptance probability of One-Tier (30/30) and Two-Tier (10/10/20/20) two One-sided Tolerance Interval Approach against Standard Deviation without and with requirement on means within (85,115)% Label Claim 2015 MBSW

  19. IV. FDA Large Sample DDU Proposal 2015 MBSW

  20. FDA Large Sample DDU Proposal • The manufacturer may use a sample size different from the USP specified sample size. • A larger number of canisters provide more precise estimation and more powerful test for quality assurance. • A small sample size between 10 and 30 of canisters may be more preferred if the product is less variable. • We extend the proposed TOSTI procedure for a variety of sample sizes becayusethe USP-compendia small sample DDU test serves only for the evaluation of the samples instead of providing quality assurance to a batch. 2015 MBSW

  21. FDA Large Sample DDU Proposal • It is based on TOSTI with one tier (30/30); • No requirement on mean values to be within (85, 115)%LC; • Basic Idea: • Pick up a Matching Point: a reference point (90% power) of a reference OC Curve (30/30 TOSTI OC Curve). • All OC curves of various sample sizes intersect at the Matching Point; • Calculate the specification for the null hypotheses (p1, p2) at α = 5%. 2015 MBSW

  22. FDA Large Sample DDU Proposal 2015 MBSW

  23. FDA Large Sample DDU Proposal • Given the power function, we develop a two-step method to determine p(n*): matching on 90% power with 30/30 OC Step 1: Solve for k subject to Step 2: Solve for p(n) from 2015 MBSW

  24. FDA Large Sample DDU Proposal • Specifications in percentage of p0 = Pr (X < 80) = Pr (X > 120) for one-tier TOSTI for various sample sizes n/n (n samples at beginning and n samples at end) with the matching point at γ* acceptance probability for lots with μ = 100, p0 = 6.25% for 30/30 sample size. 2015 MBSW

  25. V. Summary 2015 MBSW

  26. Summary • TOSTI is a batch release test which controls the quality by the coverage within (80%, 120%) of the label claim; • Furthermore, the TOSTI approach accepts a batch only if both portions of units being under-delivered (e.g. <80% efficacy concern) and over-delivered (e.g. > 120% safety concern) are controlled. • It can be adjusted for a two-tier group sequential sampling acceptance plan: • Additional acceptance probability at the 2nd tier; • More discriminating power between lots with on-target mean and off-target mean. 2015 MBSW

  27. Summary • TOSTI approach can be easily illustrated as a procedure with two one-sided tests or with a two one-sided tolerance intervals concept with exact solutions. • When using a single-tier sampling plan, the TOSTI procedure can also be extended to any sample size. The extension was made by protecting the acceptance rate for lots considered to be high quality in DDU. 2015 MBSW

  28. Main References • FDA Draft Guidance (1998) “FDA/CDER. Guidance for Industry “Nasal Spray and Inhalation Solution, Suspension, and Spray Drug Products--Chemistry, Manufacturing, and Controls Documentation”. Draft: May 1999”. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm070575.pdf • Tsong, Y., Dong, X., Shen, M., Lostritto R.T. (2015). “Quality assurance test of delivered dose uniformity of multiple-dose inhaler and dry powder inhaler drug products”. Journal of Biopharmaceutical Statistics. 25(2):328-38. • Tsong Y, Shen M, Lostritto RT, Poochikian GK (2008). Parametric two-tier sequential quality assurance test of delivery dose uniformity of multiple-dose inhaler and dry powder inhaler drug products. Journal of Biopharmaceutical Statistics, 18:5, 976-984. • USP General Chapter <601> Inhalation and Nasal Drug Products: Aerosols, Sprays, and Powders—Performance Quality Tests” http://www.pharmacopeia.cn/v29240/usp29nf24s0_c601_viewall.html 2015 MBSW

  29. Main References • Moheb M. Nasr. (2005) “Parametric Tolerance Interval Test for Delivered Dose Uniformity (DDU) Working Group Update”, Ph.D., Advisory Committee of Pharmaceutical Science October 25, 2005 • Bo Olsson (2003), “A Parametric Tolerance Interval Test for Improved Control of Delivered Dose Uniformity of Orally Inhaled and Nasal Drug Products.” IPAC-RS Presentaion, Rockville, MD 2015 MBSW

  30. Thank you! 2015 MBSW

More Related